Newly Identified Transcriptomic Biomarkers and Gene Signature of Pathological Complete Response to Induction Chemoimmunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

Abstract

Neoadjuvant therapies incorporating immune checkpoint inhibitors (ICIs) have shown promise in locally advanced head and neck squamous cell carcinoma (HNSCC). However, biomarkers for pathological complete response (pCR) remain undefined. In the CheckRad-CD8 trial (NCT03426657), we performed RNA sequencing on pre- and post-treatment biopsies from 77 locally advanced HNSCC patients treated with induction chemoimmunotherapy. Of these, 42 patients achieved pCR, while 35 had residual disease (RD). Differentially expressed genes (DEGs) and pathways were identified using DESeq2 and gene set enrichment analysis. Tumor immune microenvironment analysis, utilizing eight RNAseq deconvolution methods, assessed 266 gene signatures and 38 curated immunotherapy signatures. Baseline intratumoral CD8+ T-cell density, stromal tumor lymphocyte infiltration, and combined PD-L1 proportion score were associated with pCR. Pretreatment analysis identified 830 DEGs between pCR and RD, with T and B-cell-related pathways enriched in pCR samples. Logistic regression models indicated the significance of T and B cells and IFN-gamma signaling in predicting pCR. Furthermore, a new CheckRad-7-gene signature, with an AUC of 0.902 in the training cohort, effectively predicted pCR and survival, serving as a robust biomarker for prognosis and treatment response in HNSCC.

Keywords

head and neck squamous cell carcinoma / immunotherapy / induction therapy / pathological complete response / transcriptomic biomarkers

References

[1] H. Sung, J. Ferlay, R. L. Siegel, et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 71, no. 3 (2021): 209–249.

[2] A. Argiris and M. V. Karamouzis, “Empowering Induction Therapy for Locally Advanced Head and Neck Cancer,” Annals of Oncology 22, no. 4 (2011): 773–781.

[3] D. E. Johnson, B. Burtness, C. R. Leemans, V. W. Y. Lui, J. E. Bauman, and J. R. Grandis, “Head and Neck Squamous Cell Carcinoma,” Nature Reviews Disease Primers 6, no. 1 (2020): 92.

[4] A. T. Ruffin, H. Li, L. Vujanovic, D. P. Zandberg, R. L. Ferris, and T. C. Bruno, “Improving Head and Neck Cancer Therapies by Immunomodulation of the Tumour Microenvironment,” Nature Reviews Cancer (2022). 2022/12/01.

[5] P. M. Forde, J. Spicer, S. Lu, et al., “Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer,” New England Journal of Medicine 386, no. 21 (2022): 1973–1985.

[6] A. M. Menzies, R. N. Amaria, E. A. Rozeman, et al., “Pathological Response and Survival With Neoadjuvant Therapy in Melanoma: A Pooled Analysis From the International Neoadjuvant Melanoma Consortium (INMC),” Nature Medicine 27, no. 2 (2021): 301–309.

[7] S. Liu, H. M. Knochelmann, S. H. Lomeli, et al., “Response and Recurrence Correlates in Individuals Treated With Neoadjuvant anti-PD-1 Therapy for Resectable Oral Cavity Squamous Cell Carcinoma,” Cell Reports Medicine 2, no. 10 (2021): 100411.

[8] R. Uppaluri, K. M. Campbell, A. M. Egloff, et al., “Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial,” Clinical Cancer Research 26, no. 19 (2020): 5140–5152.

[9] T. M. Wise-Draper, S. Gulati, S. Palackdharry, et al., “Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local–Regionally Advanced Head and Neck Squamous Cell Carcinoma,” Clinical Cancer Research 28, no. 7 (2022): 1345–1352.

[10] J. D. Schoenfeld, G. J. Hanna, V. Y. Jo, et al., “Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial,” JAMA Oncology 6, no. 10 (2020): 1563–1570.

[11] R. Leidner, M. Crittenden, K. Young, et al., “Neoadjuvant Immunoradiotherapy Results in High Rate of Complete Pathological Response and Clinical to Pathological Downstaging in Locally Advanced Head and Neck Squamous Cell Carcinoma,” Journal for ImmunoTherapy of Cancer 9, no. 5 (2021): e002485.

[12] J. L. Vos, J. B. W. Elbers, O. Krijgsman, et al., “Neoadjuvant Immunotherapy With nivolumab and ipilimumab Induces Major Pathological Responses in Patients With Head and Neck Squamous Cell Carcinoma,” Nature Communications 12, no. 1 (2021): 7348.

[13] M. Hecht, M. Eckstein, S. Rutzner, et al., “Induction Chemoimmunotherapy Followed by CD8+ Immune Cell-based Patient Selection for Chemotherapy-free Radioimmunotherapy in Locally Advanced Head and Neck Cancer,” Journal for ImmunoTherapy of Cancer 10, no. 1 (2022): e003747.

[14] M. Hecht, A. O. Gostian, M. Eckstein, et al., “Safety and Efficacy of Single Cycle Induction Treatment With Cisplatin/Docetaxel/Durvalumab/Tremelimumab in Locally Advanced HNSCC: First Results of CheckRad-CD8,” Journal for ImmunoTherapy of Cancer 8, no. 2 (2020): e001378.

[15] M. Beck, S. Semrau, M. Haderlein, et al., “Differences and Similarities in the Pattern of Early Metabolic and Morphologic Response After Induction Chemo-Immunotherapy versus Induction Chemotherapy Alone in Locally Advanced Squamous Cell Head and Neck Cancer,” Cancers 14, no. 19 (2022).

[16] R. Ferrarotto, D. Bell, M. L. Rubin, et al., “Impact of Neoadjuvant Durvalumab With or Without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients With Oropharynx Cancer: CIAO Trial Results,” Clinical Cancer Research 26, no. 13 (2020): 3211–3219.

[17] Z. Chen, J. John, and J. H. Wang, “Why Responses to Immune Checkpoint Inhibitors Are Heterogeneous in Head and Neck Cancers: Contributions From Tumor-intrinsic and Host-intrinsic Factors. Mini Review,” Frontiers in Oncology 12 (2022). 2022-October-18.

[18] S. Mariathasan, S. J. Turley, D. Nickles, et al., “TGFβ Attenuates Tumour Response to PD-L1 Blockade by Contributing to Exclusion of T Cells,” Nature 554, no. 7693 (2018): 544–548.

[19] D. F. McDermott, M. A. Huseni, M. B. Atkins, et al., “Clinical Activity and Molecular Correlates of Response to atezolizumab Alone or in Combination With bevacizumab versus sunitinib in Renal Cell Carcinoma,” Nature Medicine 24, no. 6 (2018): 749–757.

[20] L. Fehrenbacher, A. Spira, M. Ballinger, et al., “Atezolizumab versus docetaxel for Patients With Previously Treated Non-small-cell Lung Cancer (POPLAR): A Multicentre, Open-label, Phase 2 Randomised Controlled Trial,” Lancet 387, no. 10030 (2016): 1837–1846.

[21] M. Ayers, J. Lunceford, M. Nebozhyn, et al., “IFN-γ-related mRNA Profile Predicts Clinical Response to PD-1 Blockade,” Journal of Clinical Investigation 127, no. 8 (2017): 2930–2940.

[22] R. J. Motzer, P. B. Robbins, T. Powles, et al., “Avelumab plus Axitinib versus Sunitinib in Advanced Renal Cell Carcinoma: Biomarker Analysis of the Phase 3 JAVELIN Renal 101 Trial,” Nature Medicine 26, no. 11 (2020): 1733–1741.

[23] Z. Gu, R. Eils, and M. Schlesner, “Complex Heatmaps Reveal Patterns and Correlations in Multidimensional Genomic Data,” Bioinformatics 32, no. 18 (2016): 2847–2849.

[24] H. Zhang and A. M. Houghton, “Good Cops Turn Bad: The Contribution of Neutrophils to Immune-checkpoint Inhibitor Treatment Failures in Cancer,” Pharmacology & Therapeutics 217 (2021): 107662.

[25] I. de Bruijn, R. Kundra, B. Mastrogiacomo, et al., “Analysis and Visualization of Longitudinal Genomic and Clinical Data From the AACR Project GENIE Biopharma Collaborative in cBioPortal,” Cancer Research 83, no. 23 (2023): 3861–3867.

[26] J. Zhang, Y. Ping, Q. Zhao, et al., “BPIFB2 is Highly Expressed in “Cold” Lung Adenocarcinoma and Decreases T Cell Chemotaxis via Activation of the STAT3 Pathway,” Molecular and Cellular Probes 62 (2022): 101804.

[27] A. Boukaba, J. Liu, C. Ward, et al., “Ectopic Expression of Meiotic Cohesin Generates Chromosome Instability in Cancer Cell Line,” PNAS 119, no. 40 (2022): e2204071119.

[28] Y. Ma and J. Hao, “Dedifferentiation of Epithelial Cells Incorporates Immune Reprogramming,” Trends in Cell Biology 31, no. 4 (2021): 237–240.

[29] S. Classen, C. Petersen, and K. Borgmann, “Crosstalk Between Immune Checkpoint and DNA Damage Response Inhibitors for Radiosensitization of Tumors,” Strahlentherapie Und Onkologie 199, no. 12 (2023): 1152–1163.

[30] M. Hecht, B. Frey, U. S. Gaipl, et al., “Machine Learning-assisted Immunophenotyping of Peripheral Blood Identifies Innate Immune Cells as Best Predictor of Response to Induction Chemo-immunotherapy in Head and Neck Squamous Cell Carcinoma—knowledge Obtained From the CheckRad-CD8 Trial,” Neoplasia 49 (2024): 100953.

[31] J. Li, J. Chen, J. Sun, and K. Li, “The Formation of NETs and Their Mechanism of Promoting Tumor Metastasis,” Journal of Oncology 2023 (2023): 7022337.

[32] J. Kreis, B. Aybey, F. Geist, B. Brors, and E. Staub, “Stromal Signals Dominate Gene Expression Signature Scores That Aim to Describe Cancer Cell–intrinsic Stemness or Mesenchymality Characteristics,” Cancer Research Communications 4, no. 2 (2024): 516–529.

[33] H. Zhao, J. Wei, and J. Sun, “Roles of TGF-β Signaling Pathway in Tumor Microenvirionment and Cancer Therapy,” International Immunopharmacology 89 (2020).

[34] B. W. Higgs, C. A. Morehouse, K. Streicher, et al., “Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients With Non–Small Cell Lung Carcinoma or Urothelial Cancer Treated With Durvalumab,” Clinical Cancer Research 24, no. 16 (2018): 3857–3866.

[35] L. Israel, A. Gluck, M. Berger, et al., “CARD10 cleavage by MALT1 Restricts Lung Carcinoma Growth in Vivo,” Oncogenesis 10, no. 4 (2021): 32.

[36] C. T. Liao, L. Y. Yang, L. Y. Lee, et al., “Whole-exome Sequencing Identifies Biosignatures That Predict Adverse Survival Outcomes in Surgically Treated Patients With Oral Cavity Squamous Cell Carcinoma,” Oral Oncology 122 (2021): 105547.

[37] D. E. Speiser, O. Chijioke, K. Schaeuble, and C. Münz, “CD4+ T Cells in Cancer,” Nature Cancer 4, no. 3 (2023): 317–329.

[38] M. Gurrea-Rubio, Q. Wu, M. A. Amin, et al., “Activation of Cytotoxic Lymphocytes Through CD6 Enhances Killing of Cancer Cells,” Cancer Immunology, Immunotherapy 73, no. 2 (2024): 34.

[39] R. R. Lovewell, J. Hong, S. Kundu, et al., “LAIR-1 Agonism as a Therapy for Acute Myeloid Leukemia,” Journal of Clinical Investigation 133, no. 22 (2023).

[40] M. I. P. Ramos, L. Tian, E. J. de Ruiter, et al., “Cancer Immunotherapy by NC410, a LAIR-2 Fc Protein Blocking human LAIR-collagen Interaction,” Elife 10 (2021). Jun 14.

[41] L. Ge, L. Xu, S. Lu, and H. Yan, “Expression and Function of Toll-Like Receptor 10 (TLR10) in Diffuse Large B Cell Lymphoma, Acute Myeloid Leukemia, and Glioma,” Medical Science Monitor 26 (2020): e921500.

[42] B. A. Helmink, S. M. Reddy, J. Gao, et al., “B Cells and Tertiary Lymphoid Structures Promote Immunotherapy Response,” Nature 577, no. 7791 (2020): 549–555.

[43] H. Li, P. H. Lin, P. Gupta, et al., “MG53 suppresses Tumor Progression and Stress Granule Formation by Modulating G3BP2 Activity in Non-small Cell Lung Cancer,” Molecular Cancer 20, no. 1 (2021): 118.

[44] J. Galon and D. Bruni, “Approaches to Treat Immune Hot, Altered and Cold Tumours With Combination Immunotherapies,” Nat Rev Drug Discovery 18, no. 3 (2019): 197–218.

[45] W.-T. Ju, R.-H. Xia, D.-W. Zhu, et al., “A Pilot Study of Neoadjuvant Combination of Anti-PD-1 Camrelizumab and VEGFR2 Inhibitor Apatinib for Locally Advanced Resectable Oral Squamous Cell Carcinoma,” Nature Communications 13, no. 1 (2022): 5378.

[46] M. H. Taylor, C.-H. Lee, V. Makker, et al., “Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors,” Journal of Clinical Oncology 38, no. 11 (2020): 1154–1163.

[47] R. Ferrarotto, M. Amit, P. Nagarajan, et al., “Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck,” Clinical Cancer Research 27, no. 16 (2021): 4557–4565.

[48] M. W. Rohaan, T. H. Borch, J. H. van den Berg, et al., “Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma,” New England Journal of Medicine 387, no. 23 (2022): 2113–2125.

[49] X. Lu, Y. A. Vano, X. Su, et al., “Silencing of Genes by Promoter Hypermethylation Shapes Tumor Microenvironment and Resistance to Immunotherapy in Clear-cell Renal Cell Carcinomas,” Cell Rep Med 4, no. 11 (2023): 101287.

[50] S. Turajlic, A. Sottoriva, T. Graham, and C. Swanton, “Resolving Genetic Heterogeneity in Cancer,” Nature Reviews Genetics 20, no. 7 (2019): 404–416.

[51] Z. Cheng, J. Ma, L. Yin, et al., “Non-invasive Molecular Imaging for Precision Diagnosis of Metastatic Lymph Nodes: Opportunities From Preclinical to Clinical Applications,” European Journal of Nuclear Medicine and Molecular Imaging 50, no. 4 (2023): 1111–1133.

[52] M. Dörrich, M. Hecht, R. Fietkau, et al., “Explainable Convolutional Neural Networks for Assessing Head and Neck Cancer Histopathology,” Diagnostic Pathology 18, no. 1 (2023): 121.

[53] S.-J. Sammut, M. Crispin-Ortuzar, S.-F. Chin, et al., “Multi-omic Machine Learning Predictor of Breast Cancer Therapy Response,” Nature 601, no. 7894 (2022): 623–629.

[54] R. Salgado, C. Denkert, S. Demaria, et al., “The Evaluation of Tumor-infiltrating Lymphocytes (TILs) in Breast Cancer: Recommendations by an International TILs Working Group 2014,” Annals of Oncology 26, no. 2 (2015): 259–271.

[55] J. S. Jang, E. Holicky, J. Lau, et al., “Application of the 3′ mRNA-Seq Using Unique Molecular Identifiers in Highly Degraded RNA Derived From Formalin-fixed, Paraffin-embedded Tissue,” BMC Genomics [Electronic Resource] 22, no. 1 (2021): 759.

[56] P. Moll, M. Ante, A. Seitz, and T. Reda, “QuantSeq 3′ mRNA Sequencing for RNA Quantification,” Nature Methods 11, no. 12 (2014): 1–3.

[57] B. Bushnell, BBMap: a fast, accurate, splice-aware aligner (2014).

[58] A. Dobin, C. A. Davis, F. Schlesinger, et al., “STAR: Ultrafast Universal RNA-seq Aligner,” Bioinformatics 29, no. 1 (2013): 15–21.

[59] Y. Liao, G. K. Smyth, and W. Shi, “featureCounts: An Efficient General Purpose Program for Assigning Sequence Reads to Genomic Features,” Bioinformatics 30, no. 7 (2014): 923–930.

[60] M. I. Love, W. Huber, and S. Anders, “Moderated Estimation of Fold Change and Dispersion for RNA-seq Data With DESeq2,” Genome Biology 15, no. 12 (2014): 550.

[61] S. Hänzelmann, R. Castelo, and J. Guinney, “GSVA: Gene Set Variation Analysis for Microarray and RNA-Seq Data,” BMC Bioinformatics [Electronic Resource] 14, no. 1 (2013): 7.

[62] D. Zeng, Z. Ye, R. Shen, et al., “IOBR: Multi-Omics Immuno-Oncology Biological Research to Decode Tumor Microenvironment and Signatures. Original Research,” Frontiers in Immunology 12 (2021). 2021-July-02.

[63] A. M. Newman, C. L. Liu, M. R. Green, et al., “Robust Enumeration of Cell Subsets From Tissue Expression Profiles,” Nature Methods 12, no. 5 (2015): 453–457.

[64] K. Yoshihara, M. Shahmoradgoli, E. Martínez, et al., “Inferring Tumour Purity and Stromal and Immune Cell Admixture From Expression Data,” Nature Communications 4, no. 1 (2013): 2612.

[65] F. Finotello, C. Mayer, C. Plattner, et al., “Molecular and Pharmacological Modulators of the Tumor Immune Contexture Revealed by Deconvolution of RNA-seq Data,” Genome Medicine 11, no. 1 (2019): 34.

[66] B. Li, E. Severson, J.-C. Pignon, et al., “Comprehensive Analyses of Tumor Immunity: Implications for Cancer Immunotherapy,” Genome Biology 17, no. 1 (2016): 174.

[67] P. Charoentong, F. Finotello, M. Angelova, et al., “Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade,” Cell Reports 18, no. 1 (2017): 248–262.

[68] E. Becht, N. A. Giraldo, L. Lacroix, et al., “Estimating the Population Abundance of Tissue-infiltrating Immune and Stromal Cell Populations Using Gene Expression,” Genome Biology 17, no. 1 (2016): 218.

[69] D. Aran, Z. Hu, and A. J. Butte, “xCell: Digitally Portraying the Tissue Cellular Heterogeneity Landscape,” Genome Biology 18, no. 1 (2017): 220.

[70] J. Racle, K. de Jonge, P. Baumgaertner, D. E. Speiser, and D. Gfeller, “Simultaneous Enumeration of Cancer and Immune Cell Types From Bulk Tumor Gene Expression Data,” Elife 6 (2017): e26476.

[71] T. Wu, E. Hu, S. Xu, et al., “clusterProfiler 4.0: A Universal Enrichment Tool for Interpreting Omics Data,” The Innovation 2, no. 3 (2021): 100141.

[72] A. Subramanian, P. Tamayo, V. K. Mootha, et al., “Gene Set Enrichment Analysis: A Knowledge-based Approach for Interpreting Genome-wide Expression Profiles,” Proceedings of the National Academy of Sciences 102, no. 43 (2005): 15545–15550.

[73] J. H. Friedman, T. Hastie, and R. Tibshirani, “Regularization Paths for Generalized Linear Models via Coordinate Descent,” Journal of Statistical Software 33, no. 1 (2010): 1–22.

[74] J.-G. Zhou, J. Yang, H. Wang, et al., “Machine Learning Based on Blood Test Biomarkers Predicts Fast Progression in Advanced NSCLC Patients Treated With Immunotherapy,” BMJ Oncology 3, no. 1 (2024): e000128.

[75] Z. Gu, “Complex Heatmap Visualization,” Imeta 1, no. 3 (2022): e43.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.